LEXINGTON, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on...
PHILADELPHIA, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery...
PIRACICABA, Brazil, Sept. 05, 2022 (GLOBE NEWSWIRE) -- Biotimize, a functional growth-stage biotechnology as a service (BaaS) company with a...
SAN CARLOS, Calif., Sept. 05, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. (NASDAQ: APGN) a clinical-stage company focused on developing innovative...
-Treatment with VCN-01 in combination with durvalumab demonstrated an acceptable safety profile and encouraging biological activity- ROCKVILLE, Md., Sept. 05,...
GLENDALE, Calif., Sept. 05, 2022 (GLOBE NEWSWIRE) -- New users often do not know the difference between Delta 8 and...
REYKJAVIK, Iceland, Sept. 05, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and...
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced...
Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children...
Devisol_Salmiakki_20mikrog_200tabl Devisol_Salmiakki_20mikrog_200tabl Devisol_Salmiakki_20mikrog_230tabl Devisol_Salmiakki_20mikrog_230tablORION CORPORATION PRESS RELEASE 5 SEPTEMBER 2022 AT 8.00 EEST Orion recalls Devisol Salmiakki dietary supplement from consumers...
Evolution of the Board of Directors Paris, September 5, 2022. The Board of Directors of Sanofi met on September 2,...
REGULATED INFORMATION As a result of a technical error in the publication dated August 26, 2022, the Board of Directors...
Poster #1400P will be presented on Sunday, September 11 by Dr. Aaron R. HansenINDIANAPOLIS, Sept. 04, 2022 (GLOBE NEWSWIRE) --...
Selected recommended phase 2 dose (RP2D) of 480 mg with ongoing enrollment in disease-specific cohorts; maximum tolerated dose (MTD) not...
New prevalence figure 22–126% higher than previous estimatesPrevalence expected to reach 592 million by 2050Researchers urge global action on smoking...
Leuven, BELGIUM, Boston, MA, US – September 2, 2022 – CET 10:30PM – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical...
Montrouge, France, September 2, 2022 DBV Technologies to Present at Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345...
SHIELD I Study did not Achieve its Primary Endpoint of Reduction in Surgical Site Infections and Mortality In an FDA...
Point-of-care technology to offer patients a timely, highly accurate status of their protection against COVID-19SAN LEANDRO, Calif., Sept. 02, 2022...
CAMBRIDGE, Mass., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics to advance...